Pharmaceutical Technology Centre · Est. 2022 · United Kingdom
Advancing the future of oncology through pharmaceutical innovation.
PTC Oncology develops formulation, process design, analytical methods and manufacturing technology for anti-cancer medicines — from small molecules to monoclonal antibody biosimilars — supporting industry, academia and the NHS.
$45B
Nivolumab market by 2033
20+
Injectable products developed
7.5%
Oncology mAb CAGR to 2033
1
UK biosimilar programme
Collaborators & Frameworks
Capabilities
Six pillars of oncology pharmaceutical excellence.
Integrated capability across the drug development lifecycle — from molecule to market — for both small molecules and biologics.
Formulation Science
Complex sterile injectables and mAb dosage forms engineered for stability, efficacy and patient safety.
Analytical Development
Method development and validation supporting product characterisation from R&D through commercial release.
Process & Scale-up
QbD- and DOE-led process design translating bench science into robust cGMP manufacturing.
Monoclonal Antibodies
Biosimilar and novel mAb development in partnership with The Antibody Company (TAC).
Technology Transfer
Structured transfer packages moving programmes between R&D, pilot, and commercial sites.
Regulatory Readiness
MHRA- and EMA-aligned documentation, supporting the pathway to marketing authorisation.
Programme
Nivolumab biosimilar development
Cell line generation · Formulation · Analytical methods · cGMP scale-up
Platform
A vertically integrated approach to oncology drug development.
Working with technical partner The Antibody Company (TAC), we deliver end-to-end programmes covering cell line development, pre-formulation and formulation, analytical method development and validation, preclinical and clinical trial supply, and industrial-scale manufacturing readiness.
Pipeline · Placeholder
A programme built for global impact.
Our lead programme is a biosimilar of Nivolumab — one of the world's most important immuno-oncology therapies, projected to reach USD 45 billion by 2033.
View investor thesis
Partner with PTC Oncology